Richard A. Norman - Concepedia

Author

Richard A. Norman

AstraZeneca (United Kingdom)ORCID

Also Known As

R. A. Norman, R. Norman, R.A. Norman, Richard A Norman, Richard A. Norman, Richard Norman, Richard A. Norman

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)University College London London School of Hygiene & Tropical Medicine AstraZeneca (United States)University of Leeds

About

Richard A. Norman is an author at AstraZeneca (United Kingdom) specializing in medicine, natural sciences, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	1.3K
2	Natural Sciences	10	10	1.2K
3	Biochemistry	10	10	1.2K
4	Cell Biology	2	2	206
5	Social Sciences	1	1	10

Richard A. Norman

Publications

Citations

H-Index

Page 1

	Year	Citations
<i>N</i>-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2<i>H</i>-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor Laurent Hennequin, J M Allen, J. Breed, Journal of Medicinal Chemistry Drug TargetPharmacotherapyPharmaceutical ChemistryMolecular PharmacologyMedicinal Chemistry	2006	358
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i> -Mutant Breast Tumors in Preclinical Models Hazel M. Weir, Robert H. Bradbury, Mandy Lawson, Cancer Research	2016	174
Design and Synthesis of Novel Lactate Dehydrogenase A Inhibitors by Fragment-Based Lead Generation Richard A. Ward, C. Brassington, Alexander L. Breeze, Journal of Medicinal Chemistry Aldo-keto ReductaseMolecular BiologyLead IdentificationChemical BiologyMedicinal Chemistry	2012	169
Optimization of a Novel Binding Motif to (<i>E</i>)-3-(3,5-Difluoro-4-((1<i>R</i>,3<i>R</i>)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1<i>H</i>-pyrido[3,4-<i>b</i>]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist Chris De Savi, Robert H. Bradbury, Alfred A. Rabow, Journal of Medicinal Chemistry Pharmaceutical SciencePharmacotherapyPositive Breast CancerPharmaceutical ChemistryMolecular Pharmacology	2015	159
Structural Insights into FGFR Kinase Isoform Selectivity: Diverse Binding Modes of AZD4547 and Ponatinib in Complex with FGFR1 and FGFR4 Julie A. Tucker, Tobias Klein, J. Breed, Structure Protein FunctionSignaling PathwayStructural InsightsReceptor Tyrosine KinaseMolecular Biology	2014	117
Imidazo[1,2-a]pyridines: A potent and selective class of cyclin-Dependent kinase inhibitors identified through structure-Based hybridisation Malcolm Anderson, John F. Beattie, Gloria A. Breault, Bioorganic & Medicinal Chemistry Letters Cyclin-dependent Kinase InhibitorsMedicinal ChemistryBioorganic ChemistryHeterocyclicBiochemistry	2003	114
Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use Harshnira Hitesh Patani, Tom D. Bunney, Nethaji Thiyagarajan, Oncotarget	2016	114
Crystal Structure of Human Thymidine Phosphorylase in Complex with a Small Molecule Inhibitor Richard A. Norman, Simon T. Barry, Michael Bate, Structure Crystal StructureBiochemistryNatural SciencesHuman Thymidine PhosphorylaseProtein X-ray Crystallography	2004	97
The <i>Mycobacterium tuberculosis ino1</i> gene is essential for growth and virulence Farahnaz Movahedzadeh, Debbie A. Smith, Richard A. Norman, Molecular Microbiology	2003	95
Prevention of MKK6-Dependent Activation by Binding to p38α MAP Kinase Jane E. Sullivan, Geoffrey A. Holdgate, Douglas A. Campbell, Biochemistry Mkk6-dependent ActivationDrug TargetMolecular RegulationChemical BiologyMedicinal Chemistry	2005	89

Page 1